The top 10 prospec­tive block­buster drug launch­es slat­ed for 2018 — Eval­u­ate

Im­age: Gilead’s John Mil­li­gan. Get­ty

Every­body in bio­phar­ma talks about un­met med­ical needs when they re­view their late-stage pipeline, but it’s the mar­ket po­ten­tial that will ei­ther whip up in­vestors or leave them cold about any in­no­va­tion. The top 10 prospec­tive drug launch­es loom­ing in 2018 — as se­lect­ed by Eval­u­ate in its 2018 pre­view — un­der­scores all the po­ten­tial of the would-be block­busters that al­ways dom­i­nate bio­phar­ma R&D news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER